Molecular targets for radiation oncology in prostate cancer

Frontiers in Oncology

Volumn 1, Issue JUL, 2011, Pages

  Wang, Tao ^a   Languino, Lucia R ^b   Lian, Jane ^a   Stein, Gary ^a   Blute, Michael ^a   FitzGerald, Thomas J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; AR; DNA methylation; ECM integrin; PrCa; Radiation; Runx2

Indexed keywords

EID: 84891594397     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00017     Document Type: Review

References (152)

1. Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., Lipson, K. E., Saffrich, R., Grone, H. J., Hallahan, D. E., Reisfeld, R. A., Debus, J., Niethammer, A. G., and Huber, P. E. (2005). Inhibition of αvβ3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin. Cancer Res. 11, 6270-6279.
2. Akech, J., Wixted, J. J., Bedard, K., van der Deen, M., Hussain, S., Guise, T. A., van Wijnen, A. J., Stein, J. L., Languino, L. R., Altieri, D. C., Pratap, J., Keller, E., Stein, G. S., and Lian, J. B. (2010). Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29, 811-821.
3. Allen, G. W., Howard, A. R., Jarrard, D. F., and Ritter, M. A. (2007). Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 110, 1405-1416.
4. Altieri, D. C. (2006). Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol. Cancer Ther. 5, 478-482.
5. Altieri, D. C., Languino, L. R., Lian, J. B., Stein, J. L., Leav, I., van Wijnen, A. J., Jiang, Z., and Stein, G. S. (2009). Prostate cancer regulatory networks. J. Cell. Biochem. 107, 845-852.
6. Baniwal, S. K., Khalid, O., Gabet, Y., Shah, R. R., Purcell, D. J., Mav, D., Kohn-Gabet, A. E., Shi, Y., Coetzee, G. A., and Frenkel, B. (2010). Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol. Cancer 9, 258.
7. Baylin, S. B., and Ohm, J. E. (2006). Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107-116.
8. Belka, C., Jendrossek, V., Pruschy, M., Vink, S., Verheij, M., and Budach, W. (2004). Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int. J. Radiat. Oncol. Biol. Phys. 58, 542-554.
9. Boccardo, F., Rubagotti, A., Barichello, M., Battaglia, M., Carmignani, G., Comeri, G., Conti, G., Cruciani, G., Dammino, S., Delliponti, U., Ditonno, P., Ferraris, V., Lilliu, S., Montefiore, F., Portoghese, F., and Spano, G. (1999). Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J. Clin. Oncol. 17, 2027-2038.
10. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Mattelaer, J., Lopez Torecilla, J., Pfeffer, J. R., Lino Cutajar, C., Zurlo, A., and Pierart, M. (2002). Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103-106.
11. Brenner, D. J., and Hall, E. J. (1999). Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43, 1095-1101.
12. Bromfield, G. P., Meng, A., Warde, P., and Bristow, R. G. (2003). Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis. 6, 73-85.
13. Burke, P. A., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Matzku, S., and DeNardo, G. L. (2002). Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62, 4263-4272.
14. Cance, W. G., Harris, J. E., Iacocca, M. V., Roche, E., Yang, X., Chang, J., Simkins, S., and Xu, L. (2000). Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin. Cancer Res. 6, 2417-2423.
15. Cao, Q., Cai, W., Li, T., Yang, Y., Chen, K., Xing, L., and Chen, X. (2006). Combination of integrin siRNA and irradiation for breast cancer therapy. Biochem. Biophys. Res. Commun. 351, 726-732.
16. Catton, C., Milosevic, M., Warde, P., Bayley, A., Crook, J., Bristow, R., and Gospodarowicz, M. (2003). Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management. Urol. Clin. North Am. 30, 751-763.
17. Chakravarti, A., Zhai, G. G., Zhang, M., Malhotra, R., Latham, D. E., Delaney, M. A., Robe, P., Nestler, U., Song, Q., and Loeffler, J. (2004). Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23, 7494-7506.
18. Choi, S. H., Cho, K. J., Nam, S. Y., Lee, S. W., Kang, J., and Kim, S. Y. (2006). Clinical significance of β1 integrin expression as a prediction marker for radiotherapy in early glottic carcinoma. Laryngoscope 116, 1228-1231.
19. Coblentz, T. R., Bissonette, E. A., Williams, K. R., and Theodorescu, D. (2002). Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer Prostatic Dis. 5, 219-225.
20. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. (1993). Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143, 390-400.
21. Cordes, N., Blaese, M. A., Plasswilm, L., Rodemann, H. P., and Van Beuningen, D. (2003). Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells in vitro. Int. J. Radiat. Biol. 79, 709-720.
22. Cordes, N., Seidler, J., Durzok, R., Geinitz, H., and Brakebusch, C. (2006). β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 25, 1378-1390.
23. Dehm, S. M., and Tindall, D. J. (2006). Molecular regulation of androgen action in prostate cancer. J. Cell. Biochem. 99, 333-344.
24. Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N. A., Tai, K. H., Wynne, C., and D'Este, C. (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 12, 451-459.
25. Dobosy, J. R., Roberts, J. L., Fu, V. X., and Jarrard, D. F. (2007). The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 177, 822-831.
26. Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., and Trotti, A. (2010). AJCC Cancer Staging Manual. New York, NY: Springer.
27. Enokida, H., Shiina, H., Urakami, S., Igawa, M., Ogishima, T., Li, L. C., Kawahara, M., Nakagawa, M., Kane, C. J., Carroll, P. R., and Dahiya, R. (2005). Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res. 11, 6582-6588.
28. Esteller, M. (2005). DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17, 55-60.
29. Feldman, B. J., and Feldman, D. (2001). The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45.
30. FitzGerald, T. J., Simon, E., and Meyer, J. (2004). Prostate carcinoma: opportunities for translational research. J. Cell. Biochem. 91, 433-442.
31. Florl, A. R., Steinhoff, C., Muller, M., Seifert, H. H., Hader, C., Engers, R., Ackermann, R., and Schulz, W. A. (2004). Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 91, 985-994.
32. Fowler, J. F., Ritter, M. A., Chappell, R. J., and Brenner, D. J. (2003). What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 56, 1093-1104.
33. Fujita, S., Watanabe, M., Kubota, T., Teramoto, T., and Kitajima, M. (1995). Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 91, 145-149.
34. Garzotto, M., Haimovitz-Friedman, A., Liao, W. C., White-Jones, M., Huryk, R., Heston, W. D., Cardon-Cardo, C., Kolesnick, R., and Fuks, Z. (1999). Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res. 59, 5194-5201.
35. Gleason, D. F., T.V.U.R. Group. (1997). "Histologic grading and staging of prostatic carcinoma," in Urologic Pathology, ed. M. Tannenbaum (Philadelphia, PA: Lea & Febiger), 171-187.
36. Goel, H. L., Alam, N., Johnson, I. N., and Languino, L. R. (2009). Integrin signaling aberrations in prostate cancer. Am. J. Transl. Res. 1, 211-220.
37. Graff, J. R., Deddens, J. A., Konicek, B. W., Colligan, B. M., Hurst, B. M., Carter, H. W., and Carter, J. H. (2001). Integrin-linked kinase expression increases with prostate tumor grade. Clin. Cancer Res. 7, 1987-1991.
38. Hanks, G. E., Pajak, T. F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., Horwitz, E. M., Lawton, C., Rosenthal, S. A., Sandler, H. M., and Shipley, W. U. (2003). Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. 21, 3972-3978.
39. Hazelbag, S., Kenter, G. G., Gorter, A., Dreef, E. J., Koopman, L. A., Violette, S. M., Weinreb, P. H., and Fleuren, G. J. (2007). Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316-324.
40. Heinlein, C. A., and Chang, C. (2004). Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308.
41. Higuchi, Y. (2003). Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. Biochem. Pharmacol. 66, 1527-1535.
42. Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A., Grignon, D. J., Brereton, H. D., Venkatesan, V., Lawton, C. A., Rosenthal, S. A., Sandler, H. M., and Shipley, W. U. (2008). Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26, 2497-2504.
43. Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687.
44. Isaacs, J. T. (1999). The biology of hormone refractory prostate cancer. Why does it develop? Urol. Clin. North Am. 26, 263-273.
45. Isaacs, J. T., Lundmo, P. I., Berges, R., Martikainen, P., Kyprianou, N., and English, H. F. (1992). Androgen regulation of programmed death of normal and malignant prostatic cells. J. Androl. 13, 457-464.
46. Janoff, D. M., Peterson, C. S., Mongoue-Tchokote, Peters L., Beer, T. M., Wersinger, E. M., Mori, M., and Garzotto, M. (2005). Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int. 96, 503-507.
47. Jarrard, D. F., Kinoshita, H., Shi, Y., Sandefur, C., Hoff, D., Meisner, L. F., Chang, C., Herman, J. G., Isaacs, W. B., and Nassif, N. (1998). Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 58, 5310-5314.
48. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
49. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300.
50. Jiang, Y., Saavedra, H. I., Holloway, M. P., Leone, G., and Altura, R. A. (2004). Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem. 279, 40511-40520.
51. Jones, P. A., and Baylin, S. B. (2002). The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428.
52. Joon, D. L., Hasegawa, M., Sikes, C., Khoo, V. S., Terry, N. H., Zagars, G. K., Meistrich, M. L., and Pollack, A. (1997). Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int. J. Radiat. Oncol. Biol. Phys. 38, 1071-1077.
53. Josson, S., Anderson, C. S., Sung, S. Y., Johnstone, P. A., Kubo, H., Hsieh, C. L., Arnold, R., Gururajan, M., Yates, C., and Chung, L. W. (2011). Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate 71, 232-240.
54. Josson, S., Matsuoka, Y., Chung, L. W., Zhau, H. E., and Wang, R. (2010). Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 21, 26-32.
55. Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., Tomsho, L. P., Peters, B. A., Pujara, K., Cordes, S., Davis, D. P., Carlton, V. E., Yuan, W., Li, L., Wang, W., Eigenbrot, C., Kaminker, J. S., Eberhard, D. A., Waring, P., Schuster, S. C., Modrusan, Z., Zhang, Z., Stokoe, D., de Sauvage, F. J., Faham, M., and Seshagiri, S. (2010). Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873.
56. Kim, K. W., Mutter, R. W., Cao, C., Albert, J. M., Freeman, M., Hallahan, D. E., and Lu, B. (2006). Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J. Biol. Chem. 281, 36883-36890.
57. Kinoshita, H., Shi, Y., Sandefur, C., Meisner, L. F., Chang, C., Choon, A., Reznikoff, C. R., Bova, G. S., Friedl, A., and Jarrard, D. F. (2000). Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60, 3623-3630.
58. Kirmizis, A., Bartley, S. M., Kuzmichev, A., Margueron, R., Reinberg, D., Green, R., and Farnham, P. J. (2004). Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18, 1592-1605.
59. Klose, R. J., and Bird, A. P. (2006). Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31, 89-97.
60. Kong, Z., Xie, D., Boike, T., Raghavan, P., Burma, S., Chen, D. J., Habib, A. A., Chakraborty, A., Hsieh, J. T., and Saha, D. (2010). Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res. 70, 2829-2839.
61. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. (1996). Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148, 1567-1576.
62. Krasny, L., Shimony, N., Tzukert, K., Gorodetsky, R., Lecht, S., Nettelbeck, D. M., and Haviv, Y. S. (2010). An in-vitro tumour microenvironment model using adhesion to type I collagen reveals Akt-dependent radiation resistance in renal cancer cells. Nephrol. Dial. Transplant. 25, 373-380.
63. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. A., Kumar, S., Lipton, S. A., Malorni, W., Nunez, G., Peter, M. E., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B., and Melino, G. (2009). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 16, 3-11.
64. Kyprianou, N., King, E. D., Bradbury, D., and Rhee, J. G. (1997). Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer 70, 341-348.
65. Lavin, M. F., Birrell, G., Chen, P., Kozlov, S., Scott, S., and Gueven, N. (2005). ATM signaling and genomic stability in response to DNA damage. Mutat. Res. 569, 123-132.
66. Leung, R. C., Liu, S. S., Chan, K. Y., Tam, K. F., Chan, K. L., Wong, L. C., and Ngan, H. Y. (2008). Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Oncol. Rep. 19, 1339-1345.
67. Li, E., Bestor, T. H., and Jaenisch, R. (1992). Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69, 915-926.
68. Li, L. C., Okino, S. T., and Dahiya, R. (2004). DNA methylation in prostate cancer. Biochim. Biophys. Acta 1704, 87-102.
69. Liao, C. P., Adisetiyo, H., Liang, M., and Roy-Burman, P. (2010). Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res. 70, 7294-7303.
70. Lim, M., Zhong, C., Yang, S., Bell, A. M., Cohen, M. B., and Roy-Burman, P. (2010). Runx2 regulates survivin expression in prostate cancer cells. Lab. Invest. 90, 222-233.
71. Lin, X., Zhang, F., Bradbury, C. M., Kaushal, A., Li, L., Spitz, D. R., Aft, R. L., and Gius, D. (2003). 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res. 63, 3413-3427.
72. Liu, S. S., Leung, R. C., Chan, K. Y., Chiu, P. M., Cheung, A. N., Tam, K. F., Ng, T. Y., Wong, L. C., and Ngan, H. Y. (2004). p73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin. Cancer Res. 10, 3309-3316.
73. Lodygin, D., Epanchintsev, A., Menssen, A., Diebold, J., and Hermeking, H. (2005). Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 65, 4218-4227.
74. Matsushima, H., Kitamura, T., Goto, T., Hosaka, Y., Homma, Y., and Kawabe, K. (1997). Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol. 158, 2278-2283.
75. McDonald, J. T., Kim, K., Norris, A. J., Vlashi, E., Phillips, T. M., Lagadec, C., Della Donna, L., Ratikan, J., Szelag, H., Hlatky, L., and McBride, W. H. (2010). Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res. 70, 8886-8895.
76. McEleny, K. R., Watson, R. W., Coffey, R. N., O'Neill, A. J., and Fitzpatrick, J. M. (2002). Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 51, 133-140.
77. McLeod, D. G., See, W. A., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Bernstein, G., Morris, C., and Armstrong, J. (2006). The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J. Urol. 176, 75-80.
78. Meiers, I., Shanks, J. H., and Bostwick, D. G. (2007). Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology 39, 299-304.
79. Meineke, V., Gilbertz, K. P., Schilperoort, K., Cordes, N., Sendler, A., Moede, T., and van Beuningen, D. (2002). Ionizing radiation modulates cell surface integrin expression and adhesion of COLO-320 cells to collagen and fibronectin in vitro. Strahlenther. Onkol. 178, 709-714.
80. Mimeault, M., and Batra, S. K. (2006). Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27, 1-22.
81. Miralbell, R., Roberts, S. A., Zubizarreta, E., and Hendry, J. H. (2011). Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int. J. Radiat. Oncol. Biol. Phys. 1-8.
82. Mishra, K. P. (2004). Cell membrane oxidative damage induced by gamma-radiation and apoptotic sensitivity. J. Environ. Pathol. Toxicol. Oncol. 23, 61-66.
83. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Bauer, J. J. (1996). Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120, 159-166.
84. Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
85. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C., and Conti, C. J. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85, 1657-1669.
86. Nelson, W. G., Yegnasubramanian, S., Agoston, A. T., Bastian, P. J., Lee, B. H., Nakayama, M., and De Marzo, A. M. (2007). Abnormal DNA methylation, epigenetics, and prostate cancer. Front. Biosci. 12, 4254-4266.
87. O'Connor, D. S., Grossman, D., Plescia, J., Li, F., Zhang, H., Villa, A., Tognin, S., Marchisio, P. C., and Altieri, D. C. (2000). Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U.S.A. 97, 13103-13107.
88. Oesterling, J. E., Jacobsen, S. J., Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P. A., Stenman, U. H., Dowell, B., Lovgren, T., and Lilja, H. (1995). Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol. 154, 1090-1095.
89. Ogata, T., Teshima, T., Kagawa, K., Hishikawa, Y., Takahashi, Y., Kawaguchi, A., Suzumoto, Y., Nojima, K., Furusawa, Y., and Matsuura, N. (2005). Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res. 65, 113-120.
90. Oktay, M. H., Oktay, K. D., Hamele-Bena, Buyuk A., and Koss, L. G. (2003). Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum. Pathol. 34, 240-245.
91. Onoda, J. M., Kantak, S. S., Piechocki, M. P., Awad, W., Chea, R., Liu, B., and Honn, K. V. (1994). Inhibition of radiation-enhanced expression of integrin and metastatic potential in B16 melanoma cells by a lipoxygenase inhibitor. Radiat. Res. 140, 410-418.
92. Pang, S. T., Weng, W. H., Flores-Morales, A., Johansson, B., Pourian, M. R., Nilsson, P., Pousette, A., Larsson, C., and Norstedt, G. (2006). Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. Prostate 66, 157-172.
93. Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., and Bissell, M. J. (2008). β1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68, 4398-4405.
94. Parker, C. C., and Dearnaley, D. P. (2003). Radical radiotherapy for prostate cancer. Cancer Treat. Rev. 29, 161-169.
95. Patra, S. K., Patra, A., Zhao, H., and Dahiya, R. (2002). DNA methyltransferase and demethylase in human prostate cancer. Mol. Carcinog. 33, 163-171.
96. Perry, A. S., Foley, R., Woodson, K., and Lawler, M. (2006). The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer 13, 357-377.
97. Pilepich, M. V., Winter, K., John, M. J., Mesic, J. B., Sause, W., Rubin, P., Lawton, C., Machtay, M., and Grignon, D. (2001). Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243-1252.
98. Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., and Grignon, D. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285-1290.
99. Pisansky, T. M. (2006). External-beam radiotherapy for localized prostate cancer. N. Engl. J. Med. 355, 1583-1591.
100. Pisansky, T. M., Kahn, M. J., Rasp, G. M., Cha, S. S., Haddock, M. G., and Bostwick, D. G. (1997). A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 79, 337-344.
101. Pollack, A., Salem, N., Ashoori, F., Hachem, P., Sangha, M., von Eschenbach, A. C., and Meistrich, M. L. (2001). Lack of prostate cancer radiosensitization by androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 51, 1002-1007.
102. Pollack, A., Zagars, G. K., and Kopplin, S. (1995). Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32, 13-20.
103. Pollack, A., Zagars, G. K., and Rosen, I. I. (1999). Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin. Oncol. 26, 150-161.
104. Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., von Eschenbach, A. C., Kuban, D. A., and Rosen, I. (2002). Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097-1105.
105. Pratap, J., Lian, J. B., and Stein, G. S. (2011). Metastatic bone disease: role of transcription factors and future targets. Bone 48, 30-36.
106. Pratap, J., Wixted, J. J., Gaur, T., Zaidi, S. K., Dobson, J., Veeraraj, K. D., Hussain, S., van Wijnen, A. J., Stein, J. L., Stein, G. S., and Lian, J. B. (2008). Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 68, 7795-7802.
107. Raffoul, J. J., Banerjee, S., Che, M., Knoll, Z. E., Doerge, D. R., Abrams, J., Kucuk, O., Sarkar, F. H., and Hillman, G. G. (2007). Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int. J. Cancer 120, 2491-2498.
108. Roach, M. III, Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., and Pilepich, M. V. (2008). Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585-591.
109. Roach, M. III. (1999). Current status of androgen suppression and radiotherapy for patients with prostate cancer. J. Steroid Biochem. Mol. Biol. 69, 239-245.
110. Roudier, M. P., Corey, E., True, L. D., Hiagno, C. S., Ott, S. M., and Vessell, R. L. (2004). Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat. Res. 118, 311-339.
111. Roy, K., Wang, L., Makrigiorgos, G. M., and Price, B. D. (2006). Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity. Biochem. Biophys. Res. Commun. 344, 821-826.
112. Rucci, N., and Teti, A. (2010). Osteomimicry: how tumor cells try to deceive the bone. Front. Biosci. (Schol. Ed.) 2, 907-915.
113. Saini, S., Majid, S., Yamamura, S., Tabatabai, Z. L., Suh, S. O., Shahryari, V., Chen, Y., Deng, G., Tanaka, Y., and Dahiya, R. (2010). Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin. Cancer Res. [Epub ahead of print].
114. Sainz, R. M., Reiter, R. J., Tan, D. X., Roldan, F., Natarajan, M., Quiros, I., Hevia, D., Rodriguez, C., and Mayo, J. C. (2008). Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. J. Pineal Res. 45, 258-270.
115. Sandler, H. M. (2004). Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy. J. Urol. 172, S38-S41; discussion S41.
116. Schellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L., Sarosdy, M. F., Vogelzang, N. J., Schellenger, J. J., and Kolvenbag, G. J. (1997a). Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 50, 330-336.
117. Schellhammer, P. F., Venner, P., Haas, G. P., Small, E. J., Nieh, P. T., Seabaugh, D. R., Patterson, A. L., Klein, E., Wajsman, Z., Furr, B., Chen, Y., and Kolvenbag, G. J. (1997b). Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J. Urol. 157, 1731-1735.
118. Scherr, D. S., Vaughan, E. D. Jr., Wei, J., Chung, M., Felsen, D., Allbright, R., and Knudsen, B. S. (1999). BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J. Urol. 162, 12-16; discussion 16-17.
119. See, W. A., and Tyrrell, C. J. (2006). The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J. Cancer Res. Clin. Oncol. 132(Suppl. 1), S7-S16.
120. Shahinian, V. B., Kuo, Y. F., Freeman, J. L., and Goodwin, J. S. (2005). Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154-164.
121. Shiloh, Y. (2003). ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3, 155-168.
122. Simon, E. L., Goel, H. L., Teider, N., Wang, T., Languino, L. R., and Fitzgerald, T. J. (2005). High dose fractionated ionizing radiation inhibits prostate cancer cell adhesion and β1 integrin expression. Prostate 64, 83-91.
123. Smith, R. A., and Giorgio, T. D. (2004). Quantitation and kinetics of CD51 surface receptor expression: implications for targeted delivery. Ann. Biomed. Eng. 32, 635-644.
124. Sreevalsan, S., Jutooru, I., Chadalapaka, G., Walker, M., and Safe, S. (2009). 1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cells. Int. J. Oncol. 35, 1191-1199.
125. Steel, G. G. (2001). The case against apoptosis. Acta Oncol 40, 968-975.
126. Szostak, M. J., and Kyprianou, N. (2000). Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol. Rep. 7, 699-706.
127. Tu, S. M., Lin, S. H., Podoloff, D. A., and Logothetis, C. J. (2010). Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin. Adv. Hematol. Oncol. 8, 341-351.
128. Udayakumar, T. S., Stoyanova, R., Hachem, P., Ahmed, M. M., and Pollack, A. (2011). Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo. Int. J. Radiat. Oncol. Biol. Phys. 79, 549-558.
129. Valicenti, R. K., Bae, K., Michalski, J., Sandler, H., Shipley, W., Lin, A., and Cox, J. (2011). Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int. J. Radiat. Oncol. Biol. Phys. 79, 1323-1329.
130. van der Deen, M., Akech, J., Wang, T., FitzGerald, T. J., Altieri, D. C., Languino, L. R., Lian, J. B., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (2010). The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFβ in prostate cancer cells. J. Cell. Biochem. 109, 828-837.
131. Veldscholte, J., Voorhorst-Ogink, M. M., Bolt-de Vries, J., van Rooij, H. C., Trapman, J., and Mulder, E. (1990). Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim. Biophys. Acta 1052, 187-194.
132. Wang, G., Reed, E., and Li, Q. Q. (2004). Apoptosis in prostate cancer: progressive and therapeutic implications (review). Int. J. Mol. Med. 14, 23-34.
133. Wang, T., Alavian, M. R., Goel, H. L., Languino, L. R., and Fitzgerald, T. J. (2008). Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation. Prostate 68, 1734-1742.
134. Wang, T., Huang, J., Alavian, M. R., Goel, H. L., Languino, L. R., and FitzGerald, T. J. (2007). αvβ3 integrin promotes resistance of prostate cancer cells to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 69, S611.
135. Weber, M., and Schubeler, D. (2007). Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr. Opin. Cell Biol. 19, 273-280.
136. Weidman, J. R., Dolinoy, D. C., Murphy, S. K., and Jirtle, R. L. (2007). Cancer susceptibility: epigenetic manifestation of environmental exposures. Cancer J. 13, 9-16.
137. Widmark, A., Klepp, O., Solberg, A., Damber, J. E., Angelsen, A., Fransson, P., Lund, J. A., Tasdemir, I., Hoyer, M., Wiklund, F., and Fossa, S. D. (2009). Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373, 301-308.
138. Wild-Bode, C., Weller, M., Rimner, A., Dichgans, J., and Wick, W. (2001). Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 61, 2744-2750.
139. Wu, C. T., Chen, W. C., Liao, S. K., Hsu, C. L., Lee, K. D., and Chen, M. F. (2007). The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr. Relat. Cancer 14, 633-643.
140. Yang, J., Fizazi, K., Peleg, S., Sikes, C. R., Raymond, A. K., Jamal, N., Hu, M., Olive, M., Martinez, L. A., Wood, C. G., Logothetis, C. J., Karsenty, G., and Navone, N. M. (2001). Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 61, 5652-5659.
141. Yegnasubramanian, S., Haffner, M. C., Zhang, Y., Gurel, B., Cornish, T. C., Wu, Z., Irizarry, R. A., Morgan, J., Hicks, J., DeWeese, T. L., Isaacs, W. B., Bova, G. S., De Marzo, A. M., and Nelson, W. G. (2008). DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 68, 8954-8967.
142. Yegnasubramanian, S., Kowalski, J., Gonzalgo, M. L., Zahurak, M., Piantadosi, S., Walsh, P. C., Bova, G. S., De Marzo, A. M., Isaacs, W. B., and Nelson, W. G. (2004). Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64, 1975-1986.
143. Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., Michalopoulos, G., Becich, M., and Luo, J. H. (2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790-2799.
144. Zagars, G. K., Pollack, A., and von Eschenbach, A. C. (2001). Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58, 233-239.
145. Zaidi, S. K., Young, D. W., Javed, A., Pratap, J., Montecino, M., van Wijnen, A., Lian, J. B., Stein, J. L., and Stein, G. S. (2007). Nuclear microenvironments in biological control and cancer. Nat. Rev. Cancer 7, 454-463.
146. Zhang, M., Coen, J. J., Suzuki, Y., Siedow, M. R., Niemierko, A., Khor, L. Y., Pollack, A., Zhang, Y., Zietman, A. L., Shipley, W. U., and Chakravarti, A. (2010a). Survivin is a potential mediator of prostate cancer metastasis. Int. J. Radiat. Oncol. Biol. Phys. 78, 1095-1103.
147. Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., and Biswal, S. (2010b). Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 9, 336-346.
148. Zhang, M., Ho, A., Hammond, E. H., Suzuki, Y., Bermudez, R. S., Lee, R. J., Pilepich, M., Shipley, W. U., Sandler, H., Khor, L. Y., Pollack, A., and Chakravarti, A. (2009). Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int. J. Radiat. Oncol. Biol. Phys. 73, 1033-1042.
149. Zhang, M., Latham, D. E., Delaney, M. A., and Chakravarti, A. (2005). Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24, 2474-2482.
150. Zhang, P., Castedo, M., Tao, Y., Violot, D., Metivier, D., Deutsch, E., Kroemer, G., and Bourhis, J. (2006). Caspase independence of radio-induced cell death. Oncogene 25, 7758-7770.
151. Zhou, H., Miki, R., Eeva, M., Fike, F. M., Seligson, D., Yang, L., Yoshimura, A., Teitell, M. A., Jamieson, C. A., and Cacalano, N. A. (2007). Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin. Cancer Res. 13, 2344-2353.
152. Zietman, A. L., Nakfoor, B. M., Prince, E. A., and Gerweck, L. E. (1997). The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J. Sci. Am. 3, 31-36.